Another misperception is that high upfront costs of treatment could be an explanation for the low-uptake. In fact, surgical procedures for other chronic diseases are performed far more often despite being similar or even more costly.
For instance, more than 120,000 surgeries for osteoarthritis (hip- and knee-replacements) are carried out every year in the UK whereas only 6,000-7,000 patients/year undergo bariatric or metabolic surgery – and of these, only about 30% have type 2 diabetes.
More than £ 1.2 bn a year is spent in the surgical treatment of osteoarthritis compared to only £10-12M for the surgical treatment of type 2 diabetes. Also, the cost of treating diabetes with drugs in the UK is about £3bn a year, with £1bn spent just for glucose-lowering drugs and additional £2bn for other drugs needed to reduce cardiovascular risk factors associated with diabetes.
Given the ability of surgery to drastically reduce the need for both these types of drugs in patients with diabetes, and even induce long-term remission of diabetes in at least 50% of patients, increasing costs from greater uptake of surgery would be balanced by the reduced expenditure for drugs.
Prejudice against people with obesity can play a major role in preventing access to surgery. In fact, a recent international study showed that while prejudice against people with obesity is ubiquitous, a gradient exists across countries. If you plot the stigma score from this study against the uptake of bariatric/metabolic surgery, there seems to be a relationship between the level of stigma and the number of bariatric/metabolic procedures being carried out.